Business Description
Biophytis S.A. is a Paris-based biotechnology company founded in 2006 that develops treatments aimed at slowing the effects of aging-related conditions, including muscle-wasting diseases and respiratory complications. Its primary drug candidate, BIO101, is being studied as a potential treatment for conditions such as sarcopenia, Duchenne Muscular Dystrophy, and severe respiratory illness linked to COVID-19. The company works alongside AFM-Telethon to advance BIO101 for Duchenne Muscular Dystrophy and has partnered with LynxKite Technologies to apply artificial intelligence to the discovery of new longevity therapies.
